QTc interval prolongation and opioid addiction therapy

Archives of Internal Medicine

Volumn 168, Issue 14, 2008, Pages 1592-

  Baker, William A ^b   Krantz, Mori J ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; LEVACETYLMETHADOL; METHADONE; OPIATE;

CLINICAL TRIAL; DRUG DEPENDENCE; DRUG FATALITY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; LETTER; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SCREENING;

ANALGESICS, OPIOID; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; OPIOID-RELATED DISORDERS; PAIN; PROGNOSIS; RISK FACTORS;

EID: 49449117771     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.14.1592     Document Type: Letter

References (5)

1. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469-2475.
2. Martell BA, Arnsten JH, Krantz MJ, et al. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95(7):915-918.
3. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am. J Cardiol. 1993;72(6);23B-25B.
4. US Food and Drug Administration. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration; 2005.
5. US Food and Drug Administration. Methadone hydrochloride; FDA alert [11/ 2006]: death, narcotic overdose, and serious cardiac arrhythmias. http://www.fda.gov/cder/drug/advisory/methadone.htm. Accessed December 24, 2007.